Sumitomo Pharma Co., Ltd. (DNPUF)
- Previous Close
2.7000 - Open
2.7000 - Bid --
- Ask --
- Day's Range
2.7000 - 2.7000 - 52 Week Range
2.2700 - 6.2100 - Volume
200 - Avg. Volume
801 - Market Cap (intraday)
1.073B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8200 - Earnings Date --
- Forward Dividend & Yield 0.10 (4.05%)
- Ex-Dividend Date Mar 30, 2023
- 1y Target Est
--
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
www.sumitomo-pharma.com6,250
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: DNPUF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNPUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNPUF
Valuation Measures
Market Cap
1.05B
Enterprise Value
3.42B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.50
Price/Book (mrq)
0.48
Enterprise Value/Revenue
0.01
Enterprise Value/EBITDA
-0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.59%
Return on Assets (ttm)
-11.64%
Return on Equity (ttm)
-34.90%
Revenue (ttm)
330.31B
Net Income Avi to Common (ttm)
-173.72B
Diluted EPS (ttm)
-2.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
42.81B
Total Debt/Equity (mrq)
119.86%
Levered Free Cash Flow (ttm)
-152.23B
Company Insights: DNPUF
DNPUF does not have Company Insights